Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field
Identifieur interne : 000361 ( Main/Corpus ); précédent : 000360; suivant : 000362Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field
Auteurs : Polly Ambermoon ; Adrian Carter ; Wayne D. Hall ; Nadeeka N. W. Dissanayaka ; John D. O'SullivanSource :
- Addiction [ 0965-2140 ] ; 2011-02.
English descriptors
- KwdEn :
Abstract
Aims To describe the prevalence, phenomenology and correlates of ‘impulse control disorders’ (ICDs) in patients with Parkinson's disease (PD) treated with dopamine replacement therapy (DRT); to assess the strength of the evidence that DRT plays a contributory causal role in these disorders; and to highlight the implications of these disorders for research in the addiction field. Methods PubMed and Web of Science databases were searched and the reference lists of papers examined. Results The prevalence of ICDs in Parkinson's patients using DRT varied between 3.5% and 13.6%, depending on the severity and range of disorders assessed. PD patients with ICDs were: generally younger; had an earlier onset of PD; had a personal or family history of substance abuse or an ICD; and were more likely to be treated with dopamine receptor agonists (DA agonists) than levodopa (l‐dopa). There is reasonable evidence that dopaminergic medications play a causal role in ICDs in that they occur at a higher rate in an otherwise low‐risk population of adults, begin after initiation of DA agonist therapy and cease upon its discontinuation. A causal relationship is biologically plausible, but the role of other factors (such as concurrent mood disorders) remain to be clarified by better‐controlled studies. Conclusions Impulse control disorders among patients with Parkinson's disease receiving dopamine replacement therapy may provide a unique opportunity for addiction researchers to study the neurobiology of impulsive forms of behaviour (such as problem gambling) that appear to be caused, in part, by the therapeutic use of dopamine receptor agonists.
Url:
DOI: 10.1111/j.1360-0443.2010.03218.x
Links to Exploration step
ISTEX:4CE84BAE539D3A0F9190551A4D76F5287C34B23DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field</title><author><name sortKey="Ambermoon, Polly" sort="Ambermoon, Polly" uniqKey="Ambermoon P" first="Polly" last="Ambermoon">Polly Ambermoon</name><affiliation><mods:affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</mods:affiliation></affiliation></author><author><name sortKey="Carter, Adrian" sort="Carter, Adrian" uniqKey="Carter A" first="Adrian" last="Carter">Adrian Carter</name><affiliation><mods:affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>The University of Melbourne, School of Psychological Sciences, Australia</mods:affiliation></affiliation></author><author><name sortKey="Hall, Wayne D" sort="Hall, Wayne D" uniqKey="Hall W" first="Wayne D." last="Hall">Wayne D. Hall</name><affiliation><mods:affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>The University of Queensland, Queensland Brain Institute, Australia</mods:affiliation></affiliation></author><author><name sortKey="Dissanayaka, Nadeeka N W" sort="Dissanayaka, Nadeeka N W" uniqKey="Dissanayaka N" first="Nadeeka N. W." last="Dissanayaka">Nadeeka N. W. Dissanayaka</name><affiliation><mods:affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurology Research Centre, Royal Brisbane Womens' Hospital, Herston, Australia</mods:affiliation></affiliation></author><author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name><affiliation><mods:affiliation>Neurology Research Centre, Royal Brisbane Womens' Hospital, Herston, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>The University of Queensland, Royal Brisbane Clinical School, School of Medicine, Australia</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4CE84BAE539D3A0F9190551A4D76F5287C34B23D</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1360-0443.2010.03218.x</idno><idno type="url">https://api.istex.fr/document/4CE84BAE539D3A0F9190551A4D76F5287C34B23D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000361</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field</title><author><name sortKey="Ambermoon, Polly" sort="Ambermoon, Polly" uniqKey="Ambermoon P" first="Polly" last="Ambermoon">Polly Ambermoon</name><affiliation><mods:affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</mods:affiliation></affiliation></author><author><name sortKey="Carter, Adrian" sort="Carter, Adrian" uniqKey="Carter A" first="Adrian" last="Carter">Adrian Carter</name><affiliation><mods:affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>The University of Melbourne, School of Psychological Sciences, Australia</mods:affiliation></affiliation></author><author><name sortKey="Hall, Wayne D" sort="Hall, Wayne D" uniqKey="Hall W" first="Wayne D." last="Hall">Wayne D. Hall</name><affiliation><mods:affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>The University of Queensland, Queensland Brain Institute, Australia</mods:affiliation></affiliation></author><author><name sortKey="Dissanayaka, Nadeeka N W" sort="Dissanayaka, Nadeeka N W" uniqKey="Dissanayaka N" first="Nadeeka N. W." last="Dissanayaka">Nadeeka N. W. Dissanayaka</name><affiliation><mods:affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurology Research Centre, Royal Brisbane Womens' Hospital, Herston, Australia</mods:affiliation></affiliation></author><author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name><affiliation><mods:affiliation>Neurology Research Centre, Royal Brisbane Womens' Hospital, Herston, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>The University of Queensland, Royal Brisbane Clinical School, School of Medicine, Australia</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Addiction</title><idno type="ISSN">0965-2140</idno><idno type="eISSN">1360-0443</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-02">2011-02</date><biblScope unit="volume">106</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="283">283</biblScope><biblScope unit="page" to="293">293</biblScope></imprint><idno type="ISSN">0965-2140</idno></series><idno type="istex">4CE84BAE539D3A0F9190551A4D76F5287C34B23D</idno><idno type="DOI">10.1111/j.1360-0443.2010.03218.x</idno><idno type="ArticleID">ADD3218</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0965-2140</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Behavioural addictions</term><term>Parkinson's disease</term><term>dopamine agonists</term><term>gambling</term><term>hypersexuality</term><term>impulse control disorders</term><term>substance abuse</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aims To describe the prevalence, phenomenology and correlates of ‘impulse control disorders’ (ICDs) in patients with Parkinson's disease (PD) treated with dopamine replacement therapy (DRT); to assess the strength of the evidence that DRT plays a contributory causal role in these disorders; and to highlight the implications of these disorders for research in the addiction field. Methods PubMed and Web of Science databases were searched and the reference lists of papers examined. Results The prevalence of ICDs in Parkinson's patients using DRT varied between 3.5% and 13.6%, depending on the severity and range of disorders assessed. PD patients with ICDs were: generally younger; had an earlier onset of PD; had a personal or family history of substance abuse or an ICD; and were more likely to be treated with dopamine receptor agonists (DA agonists) than levodopa (l‐dopa). There is reasonable evidence that dopaminergic medications play a causal role in ICDs in that they occur at a higher rate in an otherwise low‐risk population of adults, begin after initiation of DA agonist therapy and cease upon its discontinuation. A causal relationship is biologically plausible, but the role of other factors (such as concurrent mood disorders) remain to be clarified by better‐controlled studies. Conclusions Impulse control disorders among patients with Parkinson's disease receiving dopamine replacement therapy may provide a unique opportunity for addiction researchers to study the neurobiology of impulsive forms of behaviour (such as problem gambling) that appear to be caused, in part, by the therapeutic use of dopamine receptor agonists.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Polly Ambermoon</name><affiliations><json:string>The University of Queensland, UQ Centre for Clinical Research, Australia</json:string></affiliations></json:item><json:item><name>Adrian Carter</name><affiliations><json:string>The University of Queensland, UQ Centre for Clinical Research, Australia</json:string><json:string>The University of Melbourne, School of Psychological Sciences, Australia</json:string></affiliations></json:item><json:item><name>Wayne D. Hall</name><affiliations><json:string>The University of Queensland, UQ Centre for Clinical Research, Australia</json:string><json:string>The University of Queensland, Queensland Brain Institute, Australia</json:string></affiliations></json:item><json:item><name>Nadeeka N. W. Dissanayaka</name><affiliations><json:string>The University of Queensland, UQ Centre for Clinical Research, Australia</json:string><json:string>Neurology Research Centre, Royal Brisbane Womens' Hospital, Herston, Australia</json:string></affiliations></json:item><json:item><name>John D. O'Sullivan</name><affiliations><json:string>Neurology Research Centre, Royal Brisbane Womens' Hospital, Herston, Australia</json:string><json:string>The University of Queensland, Royal Brisbane Clinical School, School of Medicine, Australia</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Behavioural addictions</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine agonists</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>gambling</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>hypersexuality</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>impulse control disorders</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>substance abuse</value></json:item></subject><articleId><json:string>ADD3218</json:string></articleId><language><json:string>eng</json:string></language><abstract>Aims To describe the prevalence, phenomenology and correlates of ‘impulse control disorders’ (ICDs) in patients with Parkinson's disease (PD) treated with dopamine replacement therapy (DRT); to assess the strength of the evidence that DRT plays a contributory causal role in these disorders; and to highlight the implications of these disorders for research in the addiction field. Methods PubMed and Web of Science databases were searched and the reference lists of papers examined. Results The prevalence of ICDs in Parkinson's patients using DRT varied between 3.5% and 13.6%, depending on the severity and range of disorders assessed. PD patients with ICDs were: generally younger; had an earlier onset of PD; had a personal or family history of substance abuse or an ICD; and were more likely to be treated with dopamine receptor agonists (DA agonists) than levodopa (l‐dopa). There is reasonable evidence that dopaminergic medications play a causal role in ICDs in that they occur at a higher rate in an otherwise low‐risk population of adults, begin after initiation of DA agonist therapy and cease upon its discontinuation. A causal relationship is biologically plausible, but the role of other factors (such as concurrent mood disorders) remain to be clarified by better‐controlled studies. Conclusions Impulse control disorders among patients with Parkinson's disease receiving dopamine replacement therapy may provide a unique opportunity for addiction researchers to study the neurobiology of impulsive forms of behaviour (such as problem gambling) that appear to be caused, in part, by the therapeutic use of dopamine receptor agonists.</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>7</keywordCount><abstractCharCount>1653</abstractCharCount><pdfWordCount>6622</pdfWordCount><pdfCharCount>45088</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>250</abstractWordCount></qualityIndicators><title>Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field</title><genre><json:string>review-article</json:string></genre><host><volume>106</volume><publisherId><json:string>ADD</json:string></publisherId><pages><total>11</total><last>293</last><first>283</first></pages><issn><json:string>0965-2140</json:string></issn><issue>2</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1360-0443</json:string></eissn><title>Addiction</title><doi><json:string>10.1111/(ISSN)1360-0443</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1111/j.1360-0443.2010.03218.x</json:string></doi><id>4CE84BAE539D3A0F9190551A4D76F5287C34B23D</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/4CE84BAE539D3A0F9190551A4D76F5287C34B23D/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/4CE84BAE539D3A0F9190551A4D76F5287C34B23D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/4CE84BAE539D3A0F9190551A4D76F5287C34B23D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field</title><author><persName><forename type="first">Polly</forename><surname>Ambermoon</surname></persName><affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</affiliation></author><author><persName><forename type="first">Adrian</forename><surname>Carter</surname></persName><affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</affiliation><affiliation>The University of Melbourne, School of Psychological Sciences, Australia</affiliation></author><author><persName><forename type="first">Wayne D.</forename><surname>Hall</surname></persName><note type="correspondence"><p>Correspondence: Wayne Hall, Room 708, Building 71/918, UQCCR, The University of Queensland, Royal Brisbane Hospital Site, Herston, 4029, Queensland, Australia. E‐mail:</p></note><affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</affiliation><affiliation>The University of Queensland, Queensland Brain Institute, Australia</affiliation></author><author><persName><forename type="first">Nadeeka N. W.</forename><surname>Dissanayaka</surname></persName><affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</affiliation><affiliation>Neurology Research Centre, Royal Brisbane Womens' Hospital, Herston, Australia</affiliation></author><author><persName><forename type="first">John D.</forename><surname>O'Sullivan</surname></persName><affiliation>Neurology Research Centre, Royal Brisbane Womens' Hospital, Herston, Australia</affiliation><affiliation>The University of Queensland, Royal Brisbane Clinical School, School of Medicine, Australia</affiliation></author></analytic><monogr><title level="j">Addiction</title><idno type="pISSN">0965-2140</idno><idno type="eISSN">1360-0443</idno><idno type="DOI">10.1111/(ISSN)1360-0443</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-02"></date><biblScope unit="volume">106</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="283">283</biblScope><biblScope unit="page" to="293">293</biblScope></imprint></monogr><idno type="istex">4CE84BAE539D3A0F9190551A4D76F5287C34B23D</idno><idno type="DOI">10.1111/j.1360-0443.2010.03218.x</idno><idno type="ArticleID">ADD3218</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Aims To describe the prevalence, phenomenology and correlates of ‘impulse control disorders’ (ICDs) in patients with Parkinson's disease (PD) treated with dopamine replacement therapy (DRT); to assess the strength of the evidence that DRT plays a contributory causal role in these disorders; and to highlight the implications of these disorders for research in the addiction field. Methods PubMed and Web of Science databases were searched and the reference lists of papers examined. Results The prevalence of ICDs in Parkinson's patients using DRT varied between 3.5% and 13.6%, depending on the severity and range of disorders assessed. PD patients with ICDs were: generally younger; had an earlier onset of PD; had a personal or family history of substance abuse or an ICD; and were more likely to be treated with dopamine receptor agonists (DA agonists) than levodopa (l‐dopa). There is reasonable evidence that dopaminergic medications play a causal role in ICDs in that they occur at a higher rate in an otherwise low‐risk population of adults, begin after initiation of DA agonist therapy and cease upon its discontinuation. A causal relationship is biologically plausible, but the role of other factors (such as concurrent mood disorders) remain to be clarified by better‐controlled studies. Conclusions Impulse control disorders among patients with Parkinson's disease receiving dopamine replacement therapy may provide a unique opportunity for addiction researchers to study the neurobiology of impulsive forms of behaviour (such as problem gambling) that appear to be caused, in part, by the therapeutic use of dopamine receptor agonists.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Behavioural addictions</term></item><item><term>dopamine agonists</term></item><item><term>gambling</term></item><item><term>hypersexuality</term></item><item><term>impulse control disorders</term></item><item><term>Parkinson's disease</term></item><item><term>substance abuse</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-02">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/4CE84BAE539D3A0F9190551A4D76F5287C34B23D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1360-0443</doi><issn type="print">0965-2140</issn><issn type="electronic">1360-0443</issn><idGroup><id type="product" value="ADD"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ADDICTION">Addiction</title></titleGroup></publicationMeta><publicationMeta level="part" position="02102"><doi origin="wiley">10.1111/add.2011.106.issue-2</doi><numberingGroup><numbering type="journalVolume" number="106">106</numbering><numbering type="journalIssue" number="2">2</numbering></numberingGroup><coverDate startDate="2011-02">February 2011</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="12" status="forIssue"><doi origin="wiley">10.1111/j.1360-0443.2010.03218.x</doi><idGroup><id type="unit" value="ADD3218"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="tocHeading1">REVIEWS</title></titleGroup><copyright>© 2010 The Authors, Addiction © 2010 Society for the Study of Addiction</copyright><eventGroup><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.4.2 mode:FullText" date="2011-01-05"></event><event type="publishedOnlineAccepted" date="2010-10-06"></event><event type="publishedOnlineEarlyUnpaginated" date="2010-12-07"></event><event type="firstOnline" date="2010-12-07"></event><event type="publishedOnlineFinalForm" date="2011-01-05"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-14"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="283">283</numbering><numbering type="pageLast" number="293">293</numbering></numberingGroup><correspondenceTo>Wayne Hall, Room 708, Building 71/918, UQCCR, The University of Queensland, Royal Brisbane Hospital Site, Herston, 4029, Queensland, Australia. E‐mail: <email>w.hall@uq.edu.au</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ADD.ADD3218.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Submitted 21 June 2010; initial review completed 16 August 2010; final version accepted 19 September 2010</unparsedEditorialHistory><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="4"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="62"></count><count type="wordTotal" number="7879"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field</title><title type="shortAuthors">Polly Ambermoon et al.</title><title type="short">Impulse control disorders in PD patients</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>Polly</givenNames><familyName>Ambermoon</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1 #a2"><personName><givenNames>Adrian</givenNames><familyName>Carter</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a1 #a3" corresponding="yes"><personName><givenNames>Wayne D.</givenNames><familyName>Hall</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a1 #a4"><personName><givenNames>Nadeeka N. W.</givenNames><familyName>Dissanayaka</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a4 #a5"><personName><givenNames>John D.</givenNames><familyName>O'Sullivan</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="AU"><unparsedAffiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="AU"><unparsedAffiliation>The University of Melbourne, School of Psychological Sciences, Australia</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="AU"><unparsedAffiliation>The University of Queensland, Queensland Brain Institute, Australia</unparsedAffiliation></affiliation><affiliation xml:id="a4" countryCode="AU"><unparsedAffiliation>Neurology Research Centre, Royal Brisbane Womens' Hospital, Herston, Australia</unparsedAffiliation></affiliation><affiliation xml:id="a5" countryCode="AU"><unparsedAffiliation>The University of Queensland, Royal Brisbane Clinical School, School of Medicine, Australia</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">Behavioural addictions</keyword><keyword xml:id="k2">dopamine agonists</keyword><keyword xml:id="k3">gambling</keyword><keyword xml:id="k4">hypersexuality</keyword><keyword xml:id="k5">impulse control disorders</keyword><keyword xml:id="k6">Parkinson's disease</keyword><keyword xml:id="k7">substance abuse</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">ABSTRACT</title><p><b>Aims </b> To describe the prevalence, phenomenology and correlates of ‘impulse control disorders’ (ICDs) in patients with Parkinson's disease (PD) treated with dopamine replacement therapy (DRT); to assess the strength of the evidence that DRT plays a contributory causal role in these disorders; and to highlight the implications of these disorders for research in the addiction field.</p><p><b>Methods </b> PubMed and Web of Science databases were searched and the reference lists of papers examined.</p><p><b>Results </b> The prevalence of ICDs in Parkinson's patients using DRT varied between 3.5% and 13.6%, depending on the severity and range of disorders assessed. PD patients with ICDs were: generally younger; had an earlier onset of PD; had a personal or family history of substance abuse or an ICD; and were more likely to be treated with dopamine receptor agonists (DA agonists) than levodopa (<sc>l</sc>‐dopa). There is reasonable evidence that dopaminergic medications play a causal role in ICDs in that they occur at a higher rate in an otherwise low‐risk population of adults, begin after initiation of DA agonist therapy and cease upon its discontinuation. A causal relationship is biologically plausible, but the role of other factors (such as concurrent mood disorders) remain to be clarified by better‐controlled studies.</p><p><b>Conclusions </b> Impulse control disorders among patients with Parkinson's disease receiving dopamine replacement therapy may provide a unique opportunity for addiction researchers to study the neurobiology of impulsive forms of behaviour (such as problem gambling) that appear to be caused, in part, by the therapeutic use of dopamine receptor agonists.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field</title></titleInfo><titleInfo type="abbreviated"><title>Impulse control disorders in PD patients</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field</title></titleInfo><name type="personal"><namePart type="given">Polly</namePart><namePart type="family">Ambermoon</namePart><affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Adrian</namePart><namePart type="family">Carter</namePart><affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</affiliation><affiliation>The University of Melbourne, School of Psychological Sciences, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Wayne D.</namePart><namePart type="family">Hall</namePart><affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</affiliation><affiliation>The University of Queensland, Queensland Brain Institute, Australia</affiliation><description>Correspondence: Wayne Hall, Room 708, Building 71/918, UQCCR, The University of Queensland, Royal Brisbane Hospital Site, Herston, 4029, Queensland, Australia. E‐mail: </description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nadeeka N. W.</namePart><namePart type="family">Dissanayaka</namePart><affiliation>The University of Queensland, UQ Centre for Clinical Research, Australia</affiliation><affiliation>Neurology Research Centre, Royal Brisbane Womens' Hospital, Herston, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">John D.</namePart><namePart type="family">O'Sullivan</namePart><affiliation>Neurology Research Centre, Royal Brisbane Womens' Hospital, Herston, Australia</affiliation><affiliation>The University of Queensland, Royal Brisbane Clinical School, School of Medicine, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2011-02</dateIssued><edition>Submitted 21 June 2010; initial review completed 16 August 2010; final version accepted 19 September 2010</edition><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">4</extent><extent unit="references">62</extent><extent unit="words">7879</extent></physicalDescription><abstract lang="en">Aims To describe the prevalence, phenomenology and correlates of ‘impulse control disorders’ (ICDs) in patients with Parkinson's disease (PD) treated with dopamine replacement therapy (DRT); to assess the strength of the evidence that DRT plays a contributory causal role in these disorders; and to highlight the implications of these disorders for research in the addiction field. Methods PubMed and Web of Science databases were searched and the reference lists of papers examined. Results The prevalence of ICDs in Parkinson's patients using DRT varied between 3.5% and 13.6%, depending on the severity and range of disorders assessed. PD patients with ICDs were: generally younger; had an earlier onset of PD; had a personal or family history of substance abuse or an ICD; and were more likely to be treated with dopamine receptor agonists (DA agonists) than levodopa (l‐dopa). There is reasonable evidence that dopaminergic medications play a causal role in ICDs in that they occur at a higher rate in an otherwise low‐risk population of adults, begin after initiation of DA agonist therapy and cease upon its discontinuation. A causal relationship is biologically plausible, but the role of other factors (such as concurrent mood disorders) remain to be clarified by better‐controlled studies. Conclusions Impulse control disorders among patients with Parkinson's disease receiving dopamine replacement therapy may provide a unique opportunity for addiction researchers to study the neurobiology of impulsive forms of behaviour (such as problem gambling) that appear to be caused, in part, by the therapeutic use of dopamine receptor agonists.</abstract><subject lang="en"><genre>Keywords</genre><topic>Behavioural addictions</topic><topic>dopamine agonists</topic><topic>gambling</topic><topic>hypersexuality</topic><topic>impulse control disorders</topic><topic>Parkinson's disease</topic><topic>substance abuse</topic></subject><relatedItem type="host"><titleInfo><title>Addiction</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0965-2140</identifier><identifier type="eISSN">1360-0443</identifier><identifier type="DOI">10.1111/(ISSN)1360-0443</identifier><identifier type="PublisherID">ADD</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>283</start><end>293</end><total>11</total></extent></part></relatedItem><identifier type="istex">4CE84BAE539D3A0F9190551A4D76F5287C34B23D</identifier><identifier type="DOI">10.1111/j.1360-0443.2010.03218.x</identifier><identifier type="ArticleID">ADD3218</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2010 The Authors, Addiction © 2010 Society for the Study of Addiction</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000361 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000361 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:4CE84BAE539D3A0F9190551A4D76F5287C34B23D
|texte= Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field
}}
| This area was generated with Dilib version V0.6.23. |  |